Changzhou No.2 People's Hospital
Clinical trials sponsored by Changzhou No.2 People's Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a targeted drug boost standard chemo for aggressive lymphoma? Results expected Jul 2027 (estimated)
- Can a new drug combo outsmart resistant lymphomas? Results expected Aug 2027 (estimated)
-
Can a targeted drug combo outsmart an aggressive lymphoma?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding the targeted drug pirtobrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people newly diagnosed with a specific, harder-to-treat subtype of diffuse large B-cell lymphoma (Non-GCB DLBCL). The study will e…
Phase 2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted drug boost standard chemo for aggressive lymphoma?
Disease control Not yet recruitingThis trial is testing whether adding pirtobrutinib, a targeted drug, to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific subtype of diffuse large B-cell lymphoma (non-GCB DLBCL). The study will enroll about 34 adults with newly diagnosed di…
Phase 2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug combo outsmart resistant lymphomas?
Disease control Not yet recruitingThis phase II trial is testing whether a combination of two targeted drugs—pirtobrutinib and sonrotoclax—can shrink tumors in people with three types of B-cell lymphoma: transformed diffuse large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia/small lymphocyt…
Phase 2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC